Michael de Haan: How to turn capital into commercial success

Jun 11 2009

michiel_haan “It is the perfect blend of our proven company building experience and the capital we provide that will turn medical innovations into commercial successes within the smallest timeframe possible”.

Michiel de Haan is the founder of Atlas Venture, a venture capital company currently managing USD 2.2 billion, from offices in Boston, London, Paris and Munich. Atlas has been involved in more than 300 venture-backed companies. From 1980 to 2000 Michiel served as managing partner of Atlas Venture. His personal venture management involvement within Atlas was focused on Life Science companies in which he held numerous board seats.

As General Partner of Aescap these are their goals:

ai???We believe that we can accelerate the value creation of medical ventures by:
ai???Ai??Ai??Ai?? Providing capital and planning and arranging future investment rounds
ai???Ai??Ai??Ai?? Being a trusted sparring partner in all business disciplines
ai???Ai??Ai??Ai?? Helping to build strong management and solid teams
ai???Ai??Ai??Ai?? Determining the best strategic partner or first customer for the business
ai???Ai??Ai??Ai?? Opening up our comprehensive network in biomedics, venture capitalAi?? and other sectors
Putting the highly relevant real-life experiences that our team members have, to use for the entrepreneurs we work with. At Aescap Venture, our partners have extensive experience and proven performance to help create successful businesses. As a result of our focus and dedication in the medical market we fully understand the opportunities and threats within this challenging arena. Yet the most valuable asset is our multi-disciplinary team approach. This allows us to be a trusted, solid sparring partner on all topics of entrepreneurship.

Companies are judged on the following criteria viagra tablet tamil 231, viagra tablet tamil 231, viagra tablet tamil 231, buy generic cialis us company, buy generic cialis us company, buy generic cialis us company, buy generic cialis us company, buy generic cialis us company, buy generic cialis us company. viagra tablet tamil 231, viagra tablet tamil 231, viagra tablet tamil 231, viagra tablet tamil 231, viagra tablet tamil 231. eli 20. : key personnel, uniqueness/patents, product/market combinations, time-to-market, and envisaged exit opportunity.
We invest in companies active in the most promising segments in the medical industry. Companies using technologies that are sufficiently mature zovirax 400 mg. to yield realistic product-opportunities as well as cashflow from licensing deals. These technologies include, but are not limited to:
ai???Ai??Ai??Ai?? use of existing drugs/biosimilars for ai???newai??i?? indications
ai???Ai??Ai??Ai?? personalised medicine and its screening devices
ai???Ai??Ai??Ai?? new antibiotics
ai???Ai??Ai??Ai?? advanced drug supply of existing compounds
ai???Ai??Ai??Ai?? gene delivery for vaccines and gene therapy
ai???Ai??Ai??Ai?? implants for the treatment of handicapped vision, Parkinsonai??i??s, etc.

ai???Right now, Europe has a strong scientific basis, however, with insufficient commercialization,ai??i?? said Michiel de Haan. ‘Europeai??i??s promising biomedical investment climate convinces us that our next investments will be just as lucrative as our previous ones. Aescapai??i??s investments spread their risk over multiple products / market combinations through which they can create substantial market value. We sincerely believe that we will generate the same top quartile profits for our investors as we have done in the past.’
In 1974 Michiel received an MBA from Erasmus University in Rotterdam. From 1974 until 1980 he worked at NMB (now ING). He represented the bank in the earliest Dutch Venture Capital Funds and started NMB-Participatie, which he later bought to create Atlas Venture.

GSMA Mobile Innovation EMEA Event at Hit Barcelona

Jun 04 2009

ai???This tournament will provide an invaluable opportunity for these companies to pitch new mobile technology, product, service and business propositions to senior executives within the mobile operator and venture capital communitiesai???, Bill Gajda, Chief Commercial Officer at canadian pharmacy methylin. the GSMA.

The GSMA announced the nominees for the EMEA Tournament of the 2010 Mobile Innovation Grand Prix competition, along with a number of high-calibre industry executives who will speak at the upcoming GSMA Mobile Innovation EMEA Event, which is being held as part of the HiT Barcelona World Innovation Summit, in Barcelona, Spain, 18 ai??i?? 19 June, 2009.


The Mobile Innovation ai???Grand Prix’ was created by the GSMA as part of its Mobile Innovation initiative, with the primary goal of showcasing promising entrepreneurs from small and medium-sized companies who are introducing innovative products and services. During the EMEA event, ten companies from around the world will compete in five categories, reviewed by a panel comprised of senior inflatablesexecutives from mobile operators and venture capital firms. Two overall winners will win a trip to compete for the Mobile Innovation Grand Prix Cup at the leading event for the mobile communications industry, the Mobile World Congress, in February 2010.

The ten nominees for the EMEA leg of the 2010 Mobile Innovation Grand Prix

Most ophthacare, viagra sildenafil citrate, viagra sildenafil citrate, viagra sildenafil citrate, viagra sildenafil citrate, viagra sildenafil citrate, viagra sildenafil citrate. ophthacare, ophthacare, ophthacare, ophthacare, ophthacare, ophthacare, ophthacare. Innovative Consumer Application or Service:

Solaiemes (Spain)
Multiplied Media (Canada)
Most Innovative Embedded Mobile or Device-centric Technology
Scalado (Sweden)
IDENT Technology (Germany)
Most Innovative Carrier Infrastructure or VAS Platform
AcCells (Israel)
Novarra (USA)
Most Innovative Enterprise Application or Service
DeviceAnywhere (USA)
Apisphere (USA)
Most Innovative Product Enabling a Greener World
GreenFire Technologies (USA)
Electro Power Systems (Italy)

As a category of the Global Mobile Awards, the Mobile Innovation ‘Grand Prix’ is a tournament-style competition across four regional events culminating at the 2010 GSMA Mobile World Congress, and is designed specifically for small-to-medium companies seeking industry (operator/vendor/VC) support topamax where to buy. . Nominees will be invited to present their pitch to a global audience at Hit Barcelonaai??i??s Telecom Innovation Marketplace, that will also feature keynote speakers from top-tier companies such as Accenture, Visa, HTC Telefonica and Bebo.

The GSMA represents the interests of the worldwide mobile communications industry. Spanning 219 countries, the GSMA unites more than 750 of the world’s mobile operators, as well as 200 companies in the broader mobile ecosystem, including handset makers, software companies, equipment providers, Internet companies, and media and entertainment organisations. The GSMA is focused on innovating, incubating and creating new opportunities for its membership, all with the end goal of driving the growth of the mobile communications industry.

The 24 international companies with great growth potential

May 26 2009

24 of the most innovative start-ups in the world will meet at HiT Barcelona ai??i?? World Innovation Summit to present their business plans at the finals of the Global Entrepreneurship Competition levitra a buon prezzo, levitra a buon prezzo, levitra a buon prezzo, levitra a buon prezzo, levitra a buon prezzo, levitra a buon prezzo. maxalt for uninsured. . They have been nominated from the 100 best business plans from the most innovative companies in the world.

The international finalists were selected by the World Nominating Committee formed by 24 renowned ‘Entrepreneurship Centres’ (business schools, universities, technology parks and incubators) from around the world, each bringing a project.

In addition to these projects, 4 Spanish startups, selected from 2 entrepreneurship development programs in Spain, will participate in the finals: the 3 winners of the EmprendedorXXI Award purchase indocin. sponsored by “la Caixa” and ENISA, and the winner of the XVth Investment Forum organised by ACC1Ai??, bringing to 28 the number of contestants presenting at HiT Barcelona.

20 countries are represented in the finals of the competition and the business plans specialise in a wide range of sectors such as biotechnology, health, chemistry, telecommunications, software, education or social responsibility. The products and services designed by these emerging companies are very diversified, from storage systems for stem cells, innovative heart valves and devices for rapid detection of infectious agents to cleaning systems for oil wastes and residues or academic support platforms for students.Kids Bounce House

viagra red pill, viagra red pill, viagra red pill, viagra red pill, viagra red pill, viagra red pill, viagra red pill, viagra red pill.


The 28 finalists will present their business projects to the investment community attending HiT Barcelona: Private investors, business angels, venture capital firms, managers of public and private funds, family offices, etc.. These investors will be responsible for selecting the winners via an innovative system using a capital HiT Barcelona bank notes received at registration.inflatables for sale cheap